Communiqués Ernexa Therapeutics Inc.

Actions

ERNA

US1140824079

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 24/09/2026			Varia. 5j.	Varia. 1 janv.
3,620 ^USD	-0,82%		-7,42%	-87,93%

17/09	Ernexa Therapeutics annonce la nomination de Robert J. Spiegel à son conseil d'administration	CI
15/09	Ernexa Therapeutics publie des données précliniques positives sur l'effet modificateur de la maladie pour ERNA-201 et accélère le développement d'ERNA-101 vers les premiers essais cliniques	CI

Communiqués

17/09	Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors	AQ
15/09	Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing	AQ
14/09	Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
28/08	Ernexa Therapeutics : Initial Statement of Beneficial Ownership (Form 3)	PU
27/08	Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference	AQ
24/07	Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies	AQ
15/07	Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry	AQ
14/07	Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026	AQ
25/06	Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients	AQ
17/06	Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study	AQ
09/06	Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer	AQ
27/05	Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development	AQ
20/05	Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity	AQ
11/05	Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101	AQ
06/05	Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models	AQ
30/04	Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split	AQ
31/03	Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026	AQ
20/02	Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series	AQ
06/02	Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering	AQ
03/02	Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA	AQ
27/01	Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program	AQ
06/01	Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer	AQ
08/12	Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer	AQ
03/12	Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting	AQ
02/12	Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG	AQ